Tapinarof has not been studied during breastfeeding. Because it is poorly absorbed after topical application, it is considered a low risk to the nursing infant.[1] Do not apply tapinarof directly to the nipple and areola and ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Yaghi M, McMullan P, Truong TM, et al. Safety of dermatologic medications in pregnancy and lactation: An Update - Part II: Lactation. J Am Acad Dermatol 2024. [PubMed: 38280680]
Substance Identification
Substance Name
Tapinarof
CAS Registry Number
79338-84-4
Drug Class
Breast Feeding
Lactation
Milk, Human
Dermatological Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.